RSS | Login | Register

PAXIL SUSPENSION

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare PAXIL SUSPENSION to:

Generic Name for PAXIL SUSPENSION

Paroxetine (as HCl) 10mg/5mL; orange-flavored liq.

Legal Classification:

Pharmacological Class for PAXIL SUSPENSION

SSRI.

Manufacturer of PAXIL SUSPENSION

GlaxoSmithKline Pharmaceuticals

Indications for PAXIL SUSPENSION

Depression.

Adult dose for PAXIL SUSPENSION

Give once daily, usually in the AM, adjust by 10mg/day at 1-week intervals. Initially 20mg/day; max 50mg/day. Elderly, debilitated, severe hepatic or renal impairment: initially 10mg/day; max 40mg/day.

Children's dosing for PAXIL SUSPENSION

Not recommended.

Also:

PAXIL

PAXIL CR

Contraindications for PAXIL SUSPENSION

Concomitant pimozide, thioridazine (may cause QTc prolongation). During or within 14 days of MAOIs (including linezolid).

Precautions for PAXIL SUSPENSION

History of seizures (discontinue if occurs), mania/hypomania. Monitor for serotonin syndrome or neuroleptic malignant syndrome-like signs and symptoms; discontinue if occurs. Conditions that affect metabolism or hemodynamic response. Cardiac disease. ECT. Narrow angle glaucoma. Suicidal tendencies (monitor). Write ℞ for smallest practical amount. Avoid abrupt cessation; reduce dose gradually. Reevaluate periodically. Elderly. Labor & delivery. Pregnancy (Cat.D); avoid use. Nursing mothers.

Interactions for PAXIL SUSPENSION

See Contraindications. Do not start MAOI until at least 2 weeks after discontinuing paroxetine. Concomitant SSRIs, SNRIs, tryptophan: not recommended. Avoid alcohol. Potentiation with other protein bound drugs. Caution with drugs that affect coagulation (eg, warfarin, NSAIDs). Potentiated by cimetidine. Antagonized by fosamprenavir/ritonavir. May affect, or be affected by, drugs metabolized by CYP2D6, including tricyclic antidepressants, fluoxetine, phenothiazines, risperidone, atomoxetine, tamoxifen, Class 1C antiarrhythmics, quinidine. Monitor digoxin, phenytoin, phenobarbital, theophylline, warfarin. Reduce procyclidine dose if anticholinergic effects occur. Caution with triptans, linezolid, lithium, tramadol, St. John's wort or dopamine antagonists; may cause serotonin syndrome (eg, agitation, tachycardia, incoordination, hyperreflexia). Hormonal contraceptives and PMDD treatment: see literature.

Adverse Reactions for PAXIL SUSPENSION

GI upset, asthenia, sweating, decreased appetite, somnolence, dizziness, insomnia, nervousness, headache, decreased libido, tremor, akathisia, dry mouth, abnormal ejaculation, genital disorders, impotence, hyponatremia, abnormal bleeding, others; serious discontinuation symptoms (monitor); rare: neuroleptic malignant syndrome.

How is PAXIL SUSPENSION supplied?

CR—30
Tabs 10mg, 30mg, 40mg—30
20mg—30, 90
Susp—250mL

Related Disease:

Depression

Premenstrual dysphoric disorder

Oleptro approved for major depressive disorder (MDD)

February 03, 2010

The FDA has approved Oleptro (trazodone HCl extended-release tablets, from Labopharm), a once-daily formulation of trazodone, for the treatment of major depressive disorder (MDD) in adults.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD)

December 07, 2009

Seroquel XR (quetiapine fumarate extended-release tablets, from AstraZeneca) has been approved by the FDA as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).

Zyprexa approved for schizophrenia and bipolar I disorder in adolescents

December 07, 2009

The FDA has approved Zyprexa (olanzapine, from Lilly) tablets for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents 13-17 years of age.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.